JP6574477B2 - ルカパリブの高投与力価錠剤 - Google Patents

ルカパリブの高投与力価錠剤 Download PDF

Info

Publication number
JP6574477B2
JP6574477B2 JP2017510539A JP2017510539A JP6574477B2 JP 6574477 B2 JP6574477 B2 JP 6574477B2 JP 2017510539 A JP2017510539 A JP 2017510539A JP 2017510539 A JP2017510539 A JP 2017510539A JP 6574477 B2 JP6574477 B2 JP 6574477B2
Authority
JP
Japan
Prior art keywords
tablet
contained
range
cansylate
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017510539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525712A5 (cg-RX-API-DMAC7.html
JP2017525712A (ja
Inventor
エッター，ジェフリー
Original Assignee
クロヴィス・オンコロジー，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クロヴィス・オンコロジー，インコーポレーテッド filed Critical クロヴィス・オンコロジー，インコーポレーテッド
Publication of JP2017525712A publication Critical patent/JP2017525712A/ja
Publication of JP2017525712A5 publication Critical patent/JP2017525712A5/ja
Application granted granted Critical
Publication of JP6574477B2 publication Critical patent/JP6574477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017510539A 2014-08-22 2015-08-17 ルカパリブの高投与力価錠剤 Active JP6574477B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149084A Division JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤

Publications (3)

Publication Number Publication Date
JP2017525712A JP2017525712A (ja) 2017-09-07
JP2017525712A5 JP2017525712A5 (cg-RX-API-DMAC7.html) 2018-09-27
JP6574477B2 true JP6574477B2 (ja) 2019-09-11

Family

ID=55347324

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017510539A Active JP6574477B2 (ja) 2014-08-22 2015-08-17 ルカパリブの高投与力価錠剤
JP2019149084A Active JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja) 2014-08-22 2020-11-18 ルカパリブの高投与力価錠剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019149084A Active JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja) 2014-08-22 2020-11-18 ルカパリブの高投与力価錠剤

Country Status (20)

Country Link
US (3) US9987285B2 (cg-RX-API-DMAC7.html)
EP (1) EP3182975B1 (cg-RX-API-DMAC7.html)
JP (3) JP6574477B2 (cg-RX-API-DMAC7.html)
KR (2) KR102803917B1 (cg-RX-API-DMAC7.html)
CN (2) CN113209033A (cg-RX-API-DMAC7.html)
AU (2) AU2015305696B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017000865A2 (cg-RX-API-DMAC7.html)
CA (1) CA2955495C (cg-RX-API-DMAC7.html)
DK (1) DK3182975T3 (cg-RX-API-DMAC7.html)
ES (1) ES3048688T3 (cg-RX-API-DMAC7.html)
FI (1) FI3182975T3 (cg-RX-API-DMAC7.html)
IL (1) IL249946B (cg-RX-API-DMAC7.html)
LT (1) LT3182975T (cg-RX-API-DMAC7.html)
MX (1) MX367260B (cg-RX-API-DMAC7.html)
NZ (1) NZ728392A (cg-RX-API-DMAC7.html)
PT (1) PT3182975T (cg-RX-API-DMAC7.html)
RS (1) RS67356B1 (cg-RX-API-DMAC7.html)
RU (1) RU2705156C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201700265VA (cg-RX-API-DMAC7.html)
WO (1) WO2016028689A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021038242A (ja) * 2014-08-22 2021-03-11 クロヴィス・オンコロジー，インコーポレーテッド ルカパリブの高投与力価錠剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
EP3573990B1 (en) 2017-01-24 2024-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
TWI761476B (zh) 2017-03-27 2022-04-21 美商提薩羅有限公司 尼拉帕尼(niraparib)組合物
SG11202002113TA (en) 2017-09-26 2020-04-29 Tesaro Inc Niraparib formulations
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
MA51524A (fr) 2018-01-05 2020-11-11 Cybrexa 1 Inc Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
PE20220485A1 (es) 2019-07-10 2022-04-04 Cybrexa 3 Inc Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
WO2021220120A1 (en) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
EP4429636A1 (en) * 2021-11-10 2024-09-18 Crititech, Inc. Rucaparib particles and uses thereof
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20691B (sl) 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
MXPA05010563A (es) 2003-03-31 2005-11-23 Pfizer Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
AU2005286190A1 (en) 2004-09-22 2006-03-30 Cancer Research Technology Ltd. Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
WO2006033003A1 (en) 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
PT2534153T (pt) * 2010-02-12 2016-12-27 Pfizer Sais e polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
NZ726671A (en) 2012-04-05 2018-04-27 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
EP3182975B1 (en) 2014-08-22 2025-10-01 pharma& Schweiz GmbH High dosage strength tablets of rucaparib

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021038242A (ja) * 2014-08-22 2021-03-11 クロヴィス・オンコロジー，インコーポレーテッド ルカパリブの高投与力価錠剤

Also Published As

Publication number Publication date
NZ728392A (en) 2023-06-30
EP3182975A4 (en) 2018-04-18
EP3182975B1 (en) 2025-10-01
FI3182975T3 (fi) 2025-11-13
US10130636B2 (en) 2018-11-20
JP6797980B2 (ja) 2020-12-09
RS67356B1 (sr) 2025-11-28
RU2017109139A (ru) 2018-09-24
RU2017109139A3 (cg-RX-API-DMAC7.html) 2019-03-06
JP2020002149A (ja) 2020-01-09
EP3182975A1 (en) 2017-06-28
SG11201700265VA (en) 2017-02-27
KR20170043597A (ko) 2017-04-21
AU2019272064B2 (en) 2021-11-18
LT3182975T (lt) 2025-11-25
CA2955495C (en) 2023-09-19
CN113209033A (zh) 2021-08-06
KR20230097211A (ko) 2023-06-30
MX2017001540A (es) 2017-05-11
KR102803917B1 (ko) 2025-05-07
BR112017000865A2 (pt) 2017-12-05
ES3048688T3 (en) 2025-12-11
IL249946A0 (en) 2017-03-30
RU2705156C2 (ru) 2019-11-05
AU2015305696A1 (en) 2017-02-02
JP7127101B2 (ja) 2022-08-29
CN106794185A (zh) 2017-05-31
JP2017525712A (ja) 2017-09-07
AU2019272064A1 (en) 2019-12-19
MX367260B (es) 2019-08-12
CA2955495A1 (en) 2016-02-25
US9987285B2 (en) 2018-06-05
JP2021038242A (ja) 2021-03-11
AU2015305696B2 (en) 2019-08-29
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
US20190099430A1 (en) 2019-04-04
PT3182975T (pt) 2025-10-28
WO2016028689A1 (en) 2016-02-25
US20180200260A1 (en) 2018-07-19
US20160051561A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
JP6574477B2 (ja) ルカパリブの高投与力価錠剤
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
JP6895779B2 (ja) アジルサルタン含有固形医薬組成物
JP2016536285A (ja) アムロジピン及びバルサルタンを含む安定な医薬組成物
JP7455189B2 (ja) プレトマニド組成物
TWI418370B (zh) 溶出安定性製劑
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
US20070172521A1 (en) Levetiracetam formulations and methods for their manufacture
WO2023111187A1 (en) Pharmaceutical compositions comprising eltrombopag
JP2017520619A (ja) セリチニブ製剤
KR20110104059A (ko) 경구 생체이용률이 낮은 화합물의 예비압축된 신속-붕해 제형
WO2016139681A2 (en) Pharmaceutical composition of tizanidine and process for preparing the same
WO2025018960A1 (en) A film coated tablet of brivaracetam
HK1232807A1 (en) High dosage strength tablets of rucaparib
KR20240055103A (ko) 벰페도산의 약학 조성물
HK1232807B (en) High dosage strength tablets of rucaparib
CZ20002303A3 (cs) Perorálně podávatelné pevné ribavirinové dávkové formy a způsob jejich přípravy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180816

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180816

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190816

R150 Certificate of patent or registration of utility model

Ref document number: 6574477

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250